Method for applying enzymotherapy
SUBSTANCE: method involves making sclera pierce with injection needle 3-4 mm far from limb and then proceeding along vitreous body periphery towards epiretinal space. Collalysinum is introduced through the injection needle at a single dose of 2-10 CU directly into fibrous tissue or pouring over it. Severe fibrous transformations being the case, Collalysinum is introduced through needle bent at an angle of 30-40° with epiretinal membrane being mechanically separated or schwartotomy being concurrently done with needle tip.
EFFECT: enhanced effectiveness of treatment; minimized vitreous body injury; increased bioavailability of the preparation; accelerated treatment course.
The invention relates to the field of medicine, ophthalmology and relates to methods for enzyme therapy.
There are various ways enzyme therapy, which consists in intraocular introduction of enzyme preparations: in front of the camera, lens (intramental) and in the vitreous body (intravitreal) [1-3]. All of these methods are injection and are designed to create a desired therapeutic concentration of the enzyme preparation in pathologically altered the structure of the eyeball with minimal impact on the edge of the eye tissue.
All known methods for enzyme therapy by intraocular injection are classified depending on the localization of pathological changes in the eye. If the pathologic lesion appeared in the cornea, iris or anterior chamber of the eye, the enzyme is injected directly in front of the camera [1-3]. So, when corneal opacities of various etiologies (keratitis, wounds and burns of the cornea, disease, corneal transplant) the drug is injected in front of the camera last. This is because the contact of the enzyme with the cornea can be from two sides: both outside and inside. In this case, enzyme therapy start out with a less invasive extraocular methods of administration, which include the following: using glass the x medical films, installation, subconjunctival and parabulbar injection [4-7]. When plastic iridotsiklite when suffering iris, ciliary body, and for diabetic patients should be aware of posterior synechia, inflammatory exudate in the anterior chamber and the formed film in the area of the pupil. To do this in front of the camera administered proteolytic enzymes [1-3, 4-7]. Primary open-angle glaucoma, as evidenced by morphological and histological methods, causes degenerative and sclerotic changes in the ways of aqueous outflow [8, 9]. This leads to the formation of scar tissue with impaired activity of the native enzyme system, and therefore is substitution proteolytic enzyme therapy in the form of the introduction of kulalisena in front of the camera, according to Iauaeoeaiinou (1998). In addition, when giveme (hemorrhage in the anterior chamber) introduction enzymes in front of the camera is considered to be more rational than under the conjunctiva. Especially when total hemorrhage, leading to secondary glaucoma [10, 7]. High efficiency washing the front camera enzyme solutions at giveme was reported by many authors: Rakusin (1971), D' Abbrosio et al. (1975), T.Starck et al. (1995). Creating inside the lens high concentrations of proteases due to their entering from the outside can contribute to the full UDA the structure of the lens fibers. This is the so-called incrementally the introduction. To this end, in the equator of the capsular bag of the lens, many researchers have introduced lekozim and collalysin during extracapsular cataract extraction. Long-term results showed high efficiency of enzymes [11, 12].
There is a method of conducting enzyme therapy, in which the enzyme preparations intravitreal injected into the vitreous body. Recently, this method began to be used in the case of (hemorrhage in the vitreous and vitreoretinal fibrosis (fibrosis of the vitreous body and retina) of various origins [1-7, 13-20]. These pathological changes are the most frequent and severe complications of diabetes and the eye injury. This is due to the fact that in the case of the almost total use of enzymes in the form of a subconjunctival injection and injection under the tenon capsule did not give effective results [21-23]. In this regard, there is a need to introduce enzyme preparations directly into the vitreous body of the eyeball.
In this method, the introduction uses a variety of proteolytic enzymes: collalysin, Gamesa, streptokinase, urokinase, fibrinolizin and others [1-3, 13,15, 18, 20-30]. Now widely used collagenase having the ability to lyse fibrous tissue [1-7, 13-20]. This enzyme is known from the quality production called "collalysin and studied at subconjunctival, parabulbar, retro-bulbar methods of administration; and by electrophoresis and phonophoresis [1-3].
As for the dosage of a single intravitreal injection of kulalisena, in the literature there are various data: from 1-2 KE 10 KE [1-4, 13-16, 31].
According to known literature data, many researchers intravitreal impose other drugs (antibiotics, hormones etc) in various diseases of the eye [24, 32-34].
The main disadvantages of methods of enzymatic therapy through the introduction of proteolytic enzymes into the vitreous body is that this method does not provide the necessary bioavailability of the drug in the posterior segment of the eye (remains intact epiretinal space where a lot is formed fibrous tissue). In this context, many researchers have to repeat the introduction of the enzyme [1-3, 15, 17]. And with the re-introduction of drugs into the vitreous body has a probability of damage and the associated consequences.
Closest to the proposed subject of the invention is a method of conducting enzyme therapy by intravitreal injection of kulalisena with the aim of conservative treatment of traumatic case of the proposed Danilychev VF , according to which the enzyme preparation collalysin dose of 1 is E repeatedly injected into the vitreous body to eliminate massive hemorrhages in the vitreous body. This manipulation is performed under local anesthesia by instillation of a 1% solution dikaina, the eyeball is fixed by imposing on him wearechangela, then WCOL insulin needle in the sclera 3-4 mm from the limbus (where the projection of the flat part of the ciliary body). Next, the needle is held to the Central departments of the vitreous body and collalysin in the dosage of 1 KE is injected directly in its center. When clinical necessity manipulation repeat.
However, this technique has the following disadvantages:
1. When injected into the vitreous body has a probability of damage and the occurrence of associated consequences.
2. Collalysin causes enzymatic dissolution of the vitreous body and almost no effect on the epiretinal tissue: vitreoretinal swarthy and epiretinal membrane.
3. Low dosage of the enzyme does not provide the desired effect lizirovania fibrous tissue.
4. Due to the fact that the bioavailability of the drug is lower than with epiretinal the introduction of the drug, have to be repeated introduction from one to several times, which can lead to such complications as bleeding from damaged blood vessels.
5. Almost always followed by intravitreal injection of kulalisena vitrectomy is the surgical removal of the vitreous body, therefore, proposed the first method is not effective enough.
A new technical challenge is reducing the number of relapses, complications during and after injection of enzyme preparations; reduction of terms of treatment of patients; the more persistent therapeutic effect; the possibility of deferral or exclusion holding intraocular surgery patients with proliferative diabetic vitreoretinopathy and traumatic lesions of the eye.
To solve the problem in the way of enzyme therapy, which consists in the introduction of kulalisena through the injection needle, vcol which is carried out in the sclera at a distance of 3-4 mm from the limbus, which then hold on the periphery of the vitreous body, and then fail to epiretinal space, and the enzyme preparation at a dose of 2-10 KE once injected directly into fibrous tissue or pour out upon her, and with rough fibrous changes of the enzyme was carried out through a needle bent at an angle of 30-40 degrees tip, which simultaneously carry out the mechanical separation of epiretinal membranes or vartotojo.
The method is as follows.
Enzyme therapy according to the proposed method is carried out in the conditions of the treatment room under the control of the head binocular Ophthalmoscope (NB-2) with lens +20,0 D. Pre-diluted enzyme preparation collalysin in a dosage of from 2 to 10 To the in 0.1 ml of isotonic sodium chloride solution. Then the prepared enzyme solution trying to enter into an insulin syringe, put intradermal needle from dvukhmillimyetrovogo syringe size 0,63·32 mm At the maximum mydriasis patient will triple intelliroute anesthetic with an interval of 3-5 minutes (0.5% of p-p dikaina or 0.4% p-p of isocaine). Then fix the eyeball by imposing on him wearechangela. Then produce vcol needle in the sclera 3-4 mm from the limbus (where the projection of the flat part of the ciliary body) on 10-11 hours (figure 1). Next, a needle carried out in epiretinal space (figure 2) and the enzyme is injected directly into epiretinal fibrosis (membrane, swarty) or simply pour out on them (figure 3). If you have coarse fibrous changes, the tip intradermal needle before injection of the drug is bent at an angle of 30-40 degrees (figure 4)that allows the injection of the drug at the same time mechanically to hold the office of epiretinal membranes or vartotojo.
For the introduction of drugs (enzyme preparation of kulalisena) applicants was selected anatomical region of the eye - epiretinal space, which accommodates the liquid volume of 0.1 ml In this space, diabetes and injury in the ground and formed fibrotic changes in the form of vitreoretinal commissure and epiretinal membranes. With the introduction of Epirus is tinline space collalysin is delivered to the posterior segment of the eye, thereby increasing its bioavailability in connection with the maximum approximation of the drug to pathologically altered structures, at the same time, the vitreous body remains almost intact.
Dosage of kulalisena (2-10 S) selected on the basis of analysis of data obtained during the clinical application of the method (depending on the extent and prevalence of fibrotic changes)as the most efficient and therapeutically more effective. Dose less than 2 KE was insufficient to lizirovania fibrous tissue and dose more than 10 KE did not give additional therapeutic effect. As shown in clinical tests, the proposed method allows to obtain a stable treatment effect with a single administration of a medicinal product, which contributes to a significant reduction in the morbidity method.
The proposed method can successfully be used for dissolution of collagen - the main extracellular component vitreoretinal commissure, epiretinal membranes, due to shrinkage which occurs traction dislocation and retinal detachment, and to a lesser extent for resorption of the case.
According to the proposed method was treated 86 patients with proliferative diabetic retinopathy and traumatic lesions of the eye, of which 23 people with case (partial is hydrated and total); 2 people with preretinal hemorrhages and 61 people with proliferative changes (vitreoretinal fibrosis of varying severity and prevalence have 10 of them met epiretinal membrane). Term observation of patients was 3 years. The high efficiency of treatment of such patients by reducing the number of relapses compared with the control group by 65.2% and complications - 48.5%. In 26 cases was delayed operation (for a period of 1.5 months to 2 years); and 60 patients surgical treatment is generally not required (increased visual acuity in this group occurred in all cases from 0.1 to 1.0). Complete resorption of preretinal hemorrhages and hemophthalmos were observed in 14 patients, partial - 11; all patients (86 people) noted the lizirovania vitreoretinal fibrosis (from 30 to 95% of baseline); in all 10 cases with epiretinal membranes we were able to separate and remove them. In addition, there were no cases of anatomical damage surrounding this space normal structures of the eye.
Example 1. Patient B., 54 years old. The diagnosis of proliferative diabetic retinopathy, traction retinal detachment of the left eye. Visual acuity of the left eye = 0,02-corrected Sph+2D=0,08. December 25, 2003 it was held featur who controls the method according to the invention. Injection of the enzyme preparation in a dose of 2 KE was conducted in an outpatient setting under local anesthesia (instillation of 0.5% R-RA dikaina). When viewed 26 December 2004 left eye serene, the fundus of the eye: the retina is adjoined throughout, traction mechanism decreased (40%) from the original due to softening, loosening, and resorption of fibrous tissue, which is confirmed by ultrasonic-scan of the eyeball. Monitoring the patient for 2 years. In a stable condition, visual acuity at the last inspection = 0,4-corrected Sph+2D=0,6; the retina is adjoined throughout.
Example 2. Patient W., 51. The diagnosis of proliferative diabetic retinopathy, preretinal hemorrhage in the macular region of the left eye. Visual acuity of the left eye=0,01 eccentric. September 20, 2004, it was held, the proposed method of introduction of the enzyme (10 EC) according to the invention. This technique was performed in an outpatient setting under local anesthesia (instillation of 0.4% R-RA inakaya). During the inspection the next day the left eye of calm in the vitreous body lysed blood, the fundus of the eye is not visible yet. September 21, hemophthalmus fully visualized (90%), the fundus of the eye is well visualized, which is confirmed by ultrasonic-scan of the eyeball. Patient follow-up was 1 the od 5 months visual acuity at the last inspection of 0.5-corrected Sph+1D=1,0.
Example 3. Patient W., 20 years. The diagnosis of proliferative diabetic retinopathy, partial hemophthalmus, epiretinal membrane in the right eye. Visual acuity of the right eye = 0,1 not corrects. March 21, 2004, it was held, the proposed method according to the invention. The drug was administered in the dose of 10 KE. This intervention was conducted in an outpatient setting under local anesthesia (instillation of 0.4% R-RA inakaya curved (under 30-40 degrees) intradermal injection needle. During manipulation under the influence of the enzyme occurred softening of the epiretinal membrane. We managed to separate her from the retina and remove. When viewed 22 March 2004 right eye calm, hemophthalmus began to dissolve, and the fundus of the eye became better be viewed, epiretinal membrane is absent, and therefore the likelihood of coarse fibrous tissue is excluded, which is confirmed by ultrasonic-scan of the eyeball. Monitoring the patient was 1 year and 9 months. Positive dynamics was recorded throughout the observation period. Visual acuity at the last inspection =0,6-corrected Sph-2D=0,8.
Thus, the application of the proposed method allows to reduce the number of relapses, complications during and after injection f is mantyh drugs; to shorten the time of treatment of patients; to obtain a more stable therapeutic effect; to postpone or eliminate the conduct of intraocular surgery patients with proliferative diabetic vitreoretinopathy and traumatic lesions of the eye; and it is promising for the introduction of other medicines.
1. Danilychev SCI Ophthalmology, enzyme therapy and extracorporeal hemocorrection, 2nd ed. - SPb, 2002 - 310 C.
2. Danilychev SCI pathology of the eye, enzymes and inhibitors. - SPb.: Stroypaket, 1996 - 235 C.
3. Danilychev V.F., Knorring GO Proteolytic enzyme therapy in the pathology of the eye: method. recommendations. - SPb., 2005 - P.32.
4. Polunin G.S. Main areas of permettere in ophthalmology. J. struct. Dokl. IV the age of three. Congress of ophthalmologists. M., 1982 - S-425.
5. Polunin G.S., Angelov A.I. and other enzyme therapy in the complex treatment of the case of patients with diabetes mellitus. // Vestnik St.Petersburg University. ophthalm. - 2004 - P.14-16.
6. Polunin G.S., Kuliev I.A. Application of kulalisena in ophthalmology. // Vestnik St.Petersburg University. ophthalm. - 2000 - № 3. - P.45-47.
7. Slobozhanschina I.K., Endeav IM Fibrinoliticaskie drugs in the treatment of experimental traumatic givemy. // Vestnik St.Petersburg University. oftalmol. - 1973 - No. 3. - P.75-78.
8. Zatulin NI connective tissue and pathogenesis of primary open-angle glaucoma // VI vsesojuz. Congress of ophthalmologists: proc. the OCP. - M., 1985 - Vol.2. - P.26.
9. Zakharova G.P. Morphological changes in the tissues of the eyes with primary open-angle glaucoma // abstract. dis. Kida. the honey. Sciences. - M., 1975 - 24 C.
10. Kroll A.G. Treatment givemy and hemophthalmos after mechanical injury of the eyeball. // Oftalmol. Journe. - 1972 - No. 5. - S-335.
11. Ivanov I.I., Korovkin B.F., Markelov IM Introduction to clinical enzymopathy. - L.: Medicine, 1974 - 277 C.
12. Krasnov, M.M., S.N. Fyodorov. Achievement in the field of eye surgery and prospects of its further development // Vestnik of ophthalmology. - 1982 - No. 6. - P.7-5.
13. Evgrafov V.Y., Alyabiev GO Intraocular hemorrhage diabetic origins: contemporary views on pathogenesis and permettere. // Vestnik St.Petersburg University. ophthalm. - 2001 - no 3. - P.35-38.
14. Krasnov, M.M., Naruhina G.M. Intravitreal enzyme treatment of opacities of the vitreous body: method. recommendations. - M., 1995
15. Kupeev A.A. Traumatic hemorrhage into the vitreous body: Dis. Dr. med. Sciences. - L., 1985
16. Lickin PV, Pismenskaya VA Intraoperative application of kulalisena in the surgical treatment of vitreoretinal pathology. // Ophthalmosurgery. - 2003 - № 3. - Ñ.38-42.
17. Lickin PV "Bezirksliga" tactics of surgical treatment of retinal detachment. // Ophthalmosurgery. - 2002 - No. 2. - P.24-27.
18. Takhchidi HP, Zakharov V.D. and other Application gamasy for trims the ablation rear detachment vitreous in eyes with retinal detachment. // Ophthalmology. - 2003 - № 4. - P.14-16.
19. Fedorov, S., Glinchuk YA, Zakharov V.D. and other Vitrectomy in the treatment of severe forms of diabetic retinopathy. // Oftalmol. Journe. - 1980 - No. 8 - S-467.
20. Fedorov, S., Zakharov V.D., Glinchuk YA and other Results of operations closed vitrectomy in the clinic. // Oftalmol. Journe. - 1976 - No. 7 - S-492.
21. Gundorov R.A., Malayalam A.A., Yuzhakov A.M. Trauma of the eye. - M.: Medicine, 1986 - 367 S.
22. Gundorov R.A., Paul G.A. Penetrating injuries and bruising of the eye. - M.: Medicine, 1975 - 312 S.
23. Shtyrov LI Application fibrinolizina with traumatic hemorrhage into the vitreous body. // Abstract. dis. Kida. the honey. Sciences. - M., 1975 - 24 C.
24. Gusev Y.A., Glinchuk YA, Malyshev and V.B. have been other toxicity Study and pharmokinetic some antibiotics when they intravitreal injection in the experiment. // Ophthalmosurgery No. 2, 1992 - P.56-61.
25. Glinchuk YA, Kiselev A.V. Surgical treatment fibroblastic changes Central parts of the retina. // Ophthalmosurgery - 1993 - No. 3. - P.31-37.
26. Chazov E.I., Gundorov R.A., Romashchenko ROAD and other Immobilized streptokinase (streptococci) in the treatment of intraocular hemorrhage. // Vestnik St.Petersburg University. oftalmol. - 1982 - No. 4. - P.61-64.
27. Chapman-Smith J.S., G.W. Crock Urokinase in the management of Vitreous Haemorrage. - Brit. - J.Optalm., 1977, Vol.1, No. 8.
28. N. W. Dugmore, Raichand m Intravetrial Urokinase in the Treatment of Vitreous Hemorrge. - Amer. J. Ophtalm., 1973. Vol.1, No. 5. p.779-781.
29. J.V. Forrester Aprospective clinical study of urokinase in the treatment of vitreous hemorrage. - 2ndInternational Symposium on Urokinase. Geneva. 1981, p.19.
30. Mosgov A.A., Egorov A. Ophthalmological indications for urokinase therapy. - 2ndInternational Symposium on Urokinase. Geneva. 1981, p.14.
31. The Aznabaev M.L., Vavilov O.V. surgery of the vitreous in diabetic retinopathy and tractional detachment. // New in ophthalmology - 2003 - P.31-35
32. Astakhov US, Licoccia A.B., Sadreev THE Modern trends in medication treatment of nonproliferative diabetic retinopathy. // Clinical ophthalmology - Volume 4 No. 3, 2003, Pp.96-101.
33. Glinchuk YA, Gusev Y.A., Nedarim GN. Clinical results of a comprehensive surgical treatment of postoperative endophthalmitis method Subtotal vitrectomy and intravitreal injection of antibiotics. // Ophthalmosurgery No. 2, 1995 - P.21.
34. Jonas J.B. et. al. International injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. // Am. J. Opthalmol. - 2001. - Vol. 131. - p. 468-471.
Way for enzyme therapy in patients with proliferative diabetic retinopathy or traumatic lesions of the eye, which consists in the introduction collisionA through the injection needle, vcol which is carried out in the sclera at a distance of 3-4 mm from the limbus, characterized in that the needle then hold on the periphery of the vitreous body, and then fail to epiretinal space the TSS and collalysin at a dose of 2-10 KE once injected directly into fibrous tissue or pour on it and with rough fibrous changes of the enzyme was carried out through a needle bent at an angle of 30-40° tip which simultaneously carry out the mechanical separation of epiretinal membranes or vartotojo.
FIELD: medicine, ophthalmology, endocrinology.
SUBSTANCE: method involves instillation of 0.1% indocollir solution into conjunctival cavity in the dose 1 drop, 4 times per a day 7-10 days before carrying out the laser coagulation and for 7-10 days after the coagulation procedure. Immediately before laser coagulation indicollir solution is instilled 4 times with interval for 15 min, and immediately after laser coagulation indocollir solution is instilled one time. Method provides improving visual functions in this pathology based on recovery of impaired hemo-ophthalmic barrier owing to the power anti-inflammatory and analgesic effect of indocollir. Invention can be used in treatment of patients with edematous form of diabetic maculoretinopathy.
EFFECT: enhanced effectiveness of treatment.
2 cl, 2 ex
SUBSTANCE: the suggested eye drops based upon phospholipids in physiological solution of sodium salts contain sialic (neuramine) acid, L-carnosine and sulfated glycosamine glycans. As sulfated glycosamine glycans eye drops contain sodium salt of keratin sulfate and, also, sodium salt of chondroitin sulfate at a certain ratio of components. The innovation provides decreased evaporation of lacrimal membrane and, also, prevents pathological alterations in epithelial conjunctival and corneal cells that can lead to affected corneal stroma.
EFFECT: higher efficiency of therapy.
8 cl, 3 ex
FIELD: medicine, endocrinology, ophthalmology, pharmacy.
SUBSTANCE: invention relates to a method for treatment of diabetic retinopathy. Method involves a single administration of 1.0 ml of 2% combined hydrogel solution of chitosan ascorbate with the deacylation degree 94-98% and molecular mass 100-700 kDa and containing 200 mg of hyaluronic acid, 2 g of chondroitin sulfuric acid, 110-440 mcg of cattle serum growth factor and 50 mg of heparin in 1 l of solution through a cannula into the Tenon's space to posterior eye pole. Method provides effective treatment and decrease of adverse effects based on enhancing blood supply of posterior eye pole and anti-allergic properties of biomaterial.
EFFECT: improved method and enhanced effectiveness of treatment.
1 tbl, 1 ex
FIELD: medicine, ophthalmology.
SUBSTANCE: method involves intramuscular administration of galavite in the dose 0.1 g, once per a day for 5 days, but from 6 to 10 days - every other day, and gentamycin also in the dose 80 mg, 3 times per a day for 7 days, and bifidum - liquid bacteriophage of 791 series of production of firm "Vektor" in the dose one-half flask, 2 times per a day, one-half hour before eating, and wobenzym is given in the dose 5 tablets, 3 times per a day for 3 weeks and then in the dose 3 tablets, 3 times per a day for 3 weeks. Method provides eliminating the main clinical symptoms of these diseases based on transient suppression of hyperactivity of lipopolysaccharides of cell membrane, decreasing level of TNF-α, IL-1 and other anti-inflammatory cytokines in increasing activity of microbiocid system of neutrophile granulocytes. Invention can be used in treatment of uveitis of obscure or viral etiology.
EFFECT: improved method of treatment.
SUBSTANCE: method involves introducing medicinal mixture containing Lidocaine - 20-40 mg; Mexidol - 50-100 mg; Dalargin - 1-2 mg; Lidase - 16-32 units; Gemase 2500-5000 units and also a mixture containing: Lidocaine - 30-50 mg; Hystochrome (0.02%) - 2-4 mg; Lidase - 16-32 units into lymphatic region of injured eye orbit - into pterygopalatine fossa zone and retroaural zone alternatively in 4-5 h long pause in daily course of 6-8 procedures. Then 3-5 discrete plasmapheresis procedures are applied using no more than 20-25% of circulating plasma volume for exfusion with cellular mass being divided into two parts, one of which is activated by incubating with 3-6 mg of Polyoxydonium and the second one about 500-750 mg of Claforan at temperature of 36.8 37.0°С within 30-40 min. Ultraviolet radiation treatment is applied during reinfusion.
EFFECT: significant improvement of visual functions; stable prolonged remission period; improved lymph drainage and micro- and lymph circulation in carrying out lymphotropic therapy; increased antioxidant blood activity; inhibited free radical lipid peroxidation under ultraviolet radiation blood treatment.
SUBSTANCE: method involves determining functional activity of blood platelets before applying YAG-laser treatment. Blood platelets aggregation factor being equal to or greater than 30.0 mm, disaggregation therapy is administering one day prior to applying YAG-laser vitreolysis treatment.
EFFECT: prevented decrease in visual functions; reduced risk of occlusion complications; improved new epithelium growth process.
FIELD: organic chemistry, medicine.
SUBSTANCE: invention relates to a new using substituted derivatives of thiazole of the general formula (I): used in preparing a medicinal agent. This drug is designated for protection of mitochondria and treatment of the following diseases associated with this disease: myopathy, amyopathy, ptosis, ophthalmic atrophy, pigment retinitis, deafness, hepatomegaly, hepatic cytolysis, hypertrophic cardiomyopathy, chronic progressive ophthalmoplegia, Kirns-Seir's syndrome, Ley's disease, Leber's syndrome, Narp's syndrome, MELA's syndromes, Pirson's syndrome, liver cirrhosis and cardiac, renal or hepatic intoxication caused by medicinal agents.
EFFECT: valuable medicinal properties of compounds and drug.
10 cl, 1 ex
FIELD: medicine, ophthalmology.
SUBSTANCE: invention discloses composition of a pirenzepine-base aqueous gel with a cellulose derivative as a jelling agent used in myopia treatment. Also, invention discloses ophthalmic supplying formulation and a method for its preparing, a method for treatment and using the proposed composition in treatment of myopia. Invention provides the development of an aqueous preparing for treatment of myopia based on pirenzepine in combination with gel-like carrier that allows carrying out the effective treatment of myopia.
EFFECT: valuable medicinal properties of gel.
18 cl, 3 ex
SUBSTANCE: invention relates to water soluble polypeptides (SEQ ID NO.12) and (SEQ ID NO.7), derived from full-length tryptophanyl-tRNA-synthetase and having angiostatic activity in relation to eye neovasculatisation. Also disclosed are polynucleotides, encoding truncated polypeptide forms (SEQ ID NO.12) and (SEQ ID NO.7), and E.coli cell, expressing abovementioned polypeptides. Said polypeptides are useful in injecting angiostatic composition and kit for inhibiting of eye neovasculatisation.
EFFECT: polypeptides having non-immunogenic angiogenic properties.
22 cl, 5 dwg, 2 tbl, 5 ex
SUBSTANCE: method involves applying xanthanic pitch as active base in pharmaceutical composition possessing reepithelialization properties and optionally but not obligatory mixed with hyaluronic acid.
EFFECT: accelerated and improved process of new epithelium growth.
21 cl, 11 tbl
FIELD: medicine; medical engineering.
SUBSTANCE: method involves setting syringe body in horizontal position with additional end piece turned upward. Sealing caps are taken off from the principal and additional end pieces. Space is opened between syringe body and sealing member on the piston. The piston is moved into utmost position near tip for introducing gas. Additional rod is returned to initial position and syringe body is set in vertical position with the end piece turned down. Dosed volume of liquid drug is taken to graduation line. The principal and additional end pieces are tightly closed with cap. The syringe body is set in vertical position with the end piece turned down before usage. Space is opened between syringe body and sealing member on the piston by rotating the additional rod. The piston is displaced to dosed mark taking into account the line connecting the principal and additional graduation line. The additional rod is returned to the initial position. The liquid drug is mixed w the gas substance during 15 min. Then, sealing cap is taken off from the end piece. Needle is put on. Gas substance not mixed with the liquid drug is removed by displacing piston to dosed mark along liquid drug graduation mark.
EFFECT: reduced risk of traumatic complications.
3 cl, 2 dwg
FIELD: medicine; surgery, nephrology; neurology; clinical pharmacology.
SUBSTANCE: method can be used at injection introductions of medicinal aids into deep layers of soft tissues of lumbar area. Ultrasonic detector is applied to selected area. Area to be found in depth of tissues is detected by means of device on the screen. Different areas of skin are subject to periodical pressing by finger and appearance of wave-shaped reversible changes in skin is observed on screen under point of pressing. Part of skin is marked for injection introduction from which part the deformation wave reaches selected area more precise. Distance from skin to the area is measured and needle is introduced for the depth. 1-1,5 ml of solution is pressed out of syringe. Correctness of introduction is estimated from ultrasonic visualization of localization point which appears in tissues of medicinal infiltrate. Procedure is repeated till correct introduction is performed and that the required medicinal solutions are introduced.
EFFECT: improved precision; prevention of complications.
FIELD: medicine, in particular, equipment for injections and for taking blood or other liquids from organism, which may be also used in laboratories and enterprises in different branches of industry requiring usage of syringes for injecting liquids.
SUBSTANCE: syringe has first part made in the form of cylinder and equipped with first front end including inlet and outlet for liquid and second open end, and second part comprising stem equipped at its front end with piston and at its rear end stop, said second part being positioned for moving between first position wherein stem piston is located at site proximate front end of first part, and second position wherein stem piston is located at site distal from front end of first part. Second part also comprises pusher whose rear end has supporting surface adapted for applying pressure in first axial direction to move second part from second position to first position. First part has at its second end supporting member protruding transverse to first part and made integral therewith. Supporting member has first supporting surface for applying pressure in second axial direction opposite to first axial direction for moving second part from second position to first position, and rear supporting surface for applying pressure in said first axial direction to move second part from first position to second position. Pusher has at its front end two protruding members joined to stem through connecting links so as to define window restricted with stem stop, supporting member of first part, protruding members and rear end of pusher. Protruding members at front end of pusher are terminated with two supporting surfaces for applying pressure in second axial direction to move second part from first position to second position. First part has at least two longitudinal grooves extending from second end of first part to front end and adapted for accommodation of connecting links of pusher. Supporting member of first part has through opening shaped to provide for axial passage of protruding members.
EFFECT: convenient use owing to providing suction and liquid introduction steps for single operation.
17 cl, 7 dwg
FIELD: medical equipment, in particular, devices for injections, formed as syringes containing medicinal substances.
SUBSTANCE: apparatus is formed as syringe with hermetically sealed reservoirs containing different substances, piston mechanism including piston chamber, piston and piston stem. Chamber clearance with continuous internal surface is formed as successively arranged reservoirs or sectors with different diameters or sections, with one of reservoirs being formed as piston cylinder. Piston chambers are hermetically separated within piston chamber clearance further than line of transition of smaller diameter or other section by movable device.
EFFECT: simplified construction.
2 cl, 5 dwg
FIELD: medicinal equipment, in particular, safety syringes.
SUBSTANCE: safety syringe has cylinder with axial through opening, retainer provided within front end of cylinder, piston, needle hub, and needle. Piston positioned for sliding inside cylinder is equipped with sealing rubber member, head and flange disposed on piston in opposed relation to head. Needle hub is detachably engaged with cylinder and is provided with axial opening corresponding to that of cylinder and communicated therewith, and feeding opening adapted for communication with axial openings of needle hub and cylinder and for providing insertion of piston head. Needle has sleeve engaged with front head part of needle hub, and metal pipe engaged with sleeve. Piston has neck portion defined at its front end and arranged so that rubber sealing member tightly adheres thereto, and spatially inclined teeth. Head is made conical. Needle hub has conical front end with protrusions mating with cylinder retaining device upon rotation of cylinder. Slots are provided for engagement with inclined teeth. Bead provided in peripheral portion of feeding opening is mating with piston conical head. Protrusions are released from finger clamps upon rotation, when inclined teeth are engaged with slots.
EFFECT: simplified construction and convenient use.
4 cl, 12 dwg
FIELD: medical engineering.
SUBSTANCE: device has sealed reservoirs, containing substances, and piston mechanism, having piston cylinder, piston and piston rod. Device for moving liquid between the reservoirs is mounted in piston cylinder lumen. The device has separating piston and compression unit arranged in series. The unit designed as casing or carcass is mounted in projection of its external cylindrical part along the perimeter. Hollow internal lumen of has exit to piston projection inward from its external perimeter. The separating piston makes two connections with the piston cylinder and compression unit at the same time. The separating piston is movable into compression unit lumen with compression or change in shape taking place at the same time. The compression unit allows to make communication between reservoirs.
EFFECT: simplified design.
5 cl, 8 dwg
FIELD: medicine, gastroenterology.
SUBSTANCE: at the background of aglutenic diet and complex therapy including antisecretory, antibacterial and enzymatic preparations one should introduce biologically active additives "Normoflorin Lacto" per 20 ml twice daily and "Normoflorin Bifido" per 20 ml once daily for the period of 28-30 d. The innovation enables to efficiently correct psychoemotional status in such category of patients due to simplifying the method of therapy at excluding side effects associated with applying psychotropic preparations.
EFFECT: higher efficiency of correction.
5 ex, 1 tbl